All In Biotech

Drug Trial Radar · NCT03786081

Safety and Efficacy of Tisotumab Vedotin Monotherapy & in Combination With Other Cancer Agents in Subjects With Cervical Cancer

A Phase 1b/2 Open-Label Trial of Tisotumab Vedotin (HuMax®-TF-ADC) Monotherapy and in Combination With Other Agents in Subjects With Recurrent or Stage IVB Cervical Cancer

Last checked: Nov 20, 2026Latest source record: Jul 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Terminated

Status

Terminated

Enrollment

214

Actual

Start

Feb 27, 2019

Primary completion

Mar 19, 2026

Study completion Mar 19, 2026

Sponsor

Sponsor type
Industry
Collaborators
Genmab; European Network of Gynaecological Oncological Trial Groups (ENGOT); Belgian Gynaecological Oncology Group; GOG Foundation; Merck Sharp & Dohme LLC
First posted
Dec 24, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open label, multi-center trial of tisotumab vedotin monotherapy and in combination with bevacizumab, pembrolizumab, or carboplatin in subjects with recurrent or stage IVB cervical cancer. The trial consists of two-parts a dose escalation part and an expansion part. The expansion part of the trial will be initiated once the Recommended Phase 2 Dose (RP2D) of the combinations have been determined in the dose escalation part.

Conditions

  • Cervical Cancer

Interventions

  • Tisotumab VedotinDrug

    Given into the vein (IV)

  • BevacizumabDrug

    Given via IV

  • PembrolizumabDrug

    Given via IV

  • CarboplatinDrug

    Given via IV

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose escalation: Dose Limiting Toxicities (DLTs)Time frame: DLTs will be identified during the first treatment cycle (21 day cycles)
  2. Dose expansion: Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1)Time frame: approximately 2 years

Locations

71 sites in 10 countries. Site status is shown where the registry gives one.

  • Arizona Oncology Associates

    Phoenix, Arizona

  • Univ California, Irvine Medical Center

    Orange, California

  • Olive View - UCLA Research and Education Institute

    Sylmar, California

  • Baptist MD Anderson Cancer Center

    Jacksonville, Florida

  • Augusta University

    Augusta, Georgia

  • University of Chicago

    Chicago, Illinois

  • Indiana University School of Medicine

    Indianapolis, Indiana

  • University of Kansas Medical Center

    Westwood, Kansas

  • Oschner Clinic

    New Orleans, Louisiana

  • Dana-Farber Cancer Institute

    Boston, Massachusetts

  • Billings Clinic Cancer Center

    Billings, Montana

  • Montana Cancer Consortium

    Billings, Montana

  • SUNY Downstate Medical Center

    Brooklyn, New York

  • Memorial Sloan Kettering Cancer Center

    New York, New York

  • University of North Carolina Chapel Hill

    Chapel Hill, North Carolina

  • University of Cincinnati Physicians Group

    Cincinnati, Ohio

  • Cleveland Clinic

    Cleveland, Ohio

  • Cleveland Clinic

    Cleveland, Ohio

  • Ohio State University Wexner Medical Center

    Hilliard, Ohio

  • Fox Chase Cancer Center

    Philadelphia, Pennsylvania

  • Magee-Womens Hospital of UPMC

    Pittsburgh, Pennsylvania

  • Brown University - Women's and Infant Hospital

    Providence, Rhode Island

  • St Francis Hospital Cancer Center

    Greenville, South Carolina

  • Huntsman Cancer Center

    Salt Lake City, Utah

  • Carilion Clinic

    Roanoke, Virginia

  • AZ Sint-Jan

    Bruges, Belgium

  • Cliniques universitaires Saint-Luc

    Brussels, Belgium

  • Grand Hôpital de Charleroi

    Charleroi, Belgium

  • Universitair Ziekenhuis Antwerpen (UZA)

    Edegem, Belgium

  • Universitair Ziekenhuis Gent

    Ghent, Belgium

  • UZ Leuven

    Leuven, Belgium

  • Universitaire Ziekenhuizen Leuven,

    Leuven, Belgium

  • Centre Hospitalier de l'Ardenne

    Libramont, Belgium

  • Centre Hospitalier Universitaire (CHU) de Liège

    Liège, Belgium

  • Grand Hôpital de Charleroi

    Loverval, Belgium

  • CHU UCL Namur

    Namur, Belgium

  • Sainte-Elisabeth

    Namur, Belgium

  • Fakultni nemocnice Olomouc

    Olomouc, Czechia

  • Fakultni nemocnice Olomouc

    Olomouc, Czechia

  • Fakultni nemocnice Ostrava

    Ostrava-Poruba, Czechia

Showing 40 of 71 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.